How has been the historical performance of Jubilant Pharmo?

Answer:The historical performance of Jubilant Pharmo shows a fluctuating trend in key financial metrics over the years, with notable improvements in recent periods.

Breakdown:
Jubilant Pharmo's net sales have increased from 6,130.16 Cr in Mar'22 to 7,234.50 Cr in Mar'25, reflecting a positive growth trajectory. The total operating income followed a similar pattern, rising from 6,130.16 Cr to 7,234.50 Cr during the same period. However, the total expenditure has also grown, from 4,973.83 Cr in Mar'22 to 6,060.80 Cr in Mar'25, impacting the operating profit, which saw fluctuations, peaking at 1,230.50 Cr in Mar'25 after a dip in previous years. The profit before tax surged to 981.10 Cr in Mar'25, a significant recovery from just 15.53 Cr in Mar'23. Consequently, the profit after tax also rebounded to 836.80 Cr in Mar'25, compared to a loss of 77.13 Cr in Mar'23. The company's total assets increased from 9,829.60 Cr in Mar'22 to 12,499.00 Cr in Mar'25, while total liabilities rose from 9,829.60 Cr to 12,499.00 Cr in the same timeframe. Cash flow from operating activities improved to 1,072.00 Cr in Mar'25, indicating stronger operational efficiency. Overall, Jubilant Pharmo's financial performance has shown resilience and recovery, particularly in the last fiscal year.